Soliton to Present Poster on Pivotal Cellulite Data at Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting

Rhea-AI Summary

Soliton, Inc. (Nasdaq: SOLY) announced its acceptance to present pivotal cellulite data at the Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting, scheduled for October 9-11, 2020. The online poster presentation will feature findings from a multi-center pivotal trial titled "Improvement in the Appearance of Cellulite Depressions and Skin Laxity Resulting from a Single Treatment with Acoustic Subcision". Soliton's technology licensed from MD Anderson aims to enhance treatments for conditions like unwanted tattoos and cellulite.

HOUSTON, Oct. 5, 2020 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary aesthetic platform technology, today announced the Company has been accepted to present its pivotal cellulite data via an online poster during the Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting, taking place October 9-11, 2020.

The poster presentation titled, "Improvement in the Appearance of Cellulite Depressions and Skin Laxity Resulting from a Single Treatment with Acoustic Subcision: Findings from a Multi-Center Pivotal Trial", will be available to registered attendees beginning October 9, 2020 at 8:00 a.m. ET.

------------------------
Join our more than 200K subscribers here to follow the Company: https://soly-investors.com
------------------------

About Soliton, Inc.

Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer Center. The Company's first FDA cleared commercial product will use rapid pulses of acoustic shockwaves as an accessory to lasers for the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing the Rapid Acoustic Pulse ("RAP") device to the market. The Company believes this "Soliton" method has the potential to lower tattoo removal costs for patients, while increasing profitability to practitioners, compared to current laser removal methods. Soliton has completed a clinical study using the RAP device to improve the appearance of cellulite and is investigating potential additional capabilities of the RAP technology. The device is currently cleared in the United States only for use in tattoo removal and is not yet cleared for use to address cellulite.

For more information about the Company, please visit: http://www.soliton.com

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which statements involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, our ability to participate in the Virtual American Society for Dermatologic Surgery 2020 Annual Meeting. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results or outcomes may prove to be materially different from the expectations expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' "would," ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed in our filings with the Securities and Exchange Commission ("SEC"), including under the heading " Risk Factors" in the Form 10-K for year ended December 31, 2019 filed with the SEC and as updated in our Form 10-Q filings and in our other filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

View original content to download multimedia:http://www.prnewswire.com/news-releases/soliton-to-present-poster-on-pivotal-cellulite-data-at-virtual-american-society-for-dermatologic-surgery-asds-2020-annual-meeting-301144854.html

SOURCE Soliton, Inc.

FAQ

What data will Soliton present at the ASDS 2020 Annual Meeting?

Soliton will present pivotal cellulite data from a multi-center trial at the Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting.

When will Soliton's poster presentation be available?

The poster presentation will be available to registered attendees starting October 9, 2020, at 8:00 a.m. ET.

What is the title of Soliton's poster presentation?

The title of the poster presentation is "Improvement in the Appearance of Cellulite Depressions and Skin Laxity Resulting from a Single Treatment with Acoustic Subcision: Findings from a Multi-Center Pivotal Trial."

What is Soliton's focus in medical devices?

Soliton focuses on developing medical devices utilizing acoustic shockwave technology for the treatment of cellulite and tattoo removal.

How does Soliton's technology potentially benefit patients?

Soliton's technology is designed to lower tattoo removal costs for patients and increase profitability for practitioners compared to traditional laser methods.